Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047133 | 0.90 | SIGMAR1 (0.50) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7047321 | 0.89 | SIGMAR1 (0.48) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7049217 | 0.89 | SIGMAR1 (0.48) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7047217 | 0.88 | SIGMAR1 (0.48) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7049635 | 0.88 | SIGMAR1 (0.48) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7053017 | 0.87 | SIGMAR1 (0.52) | SIGMAR1HSD11B1LMNASMN1; SMN2KDM4E | |
| SCHEMBL27574371 | 0.86 | SIGMAR1 (0.49) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7037447 | 0.86 | MTTP (0.56) | SIGMAR1 | |
| SCHEMBL7048327 | 0.86 | SIGMAR1 (0.49) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7048504 | 0.85 | MTTP (0.47) | SIGMAR1HSD11B1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| CN-1414956-A | Substituted piperazine derivatives as MIP inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | SIGMAR1 671/4885HSD11B1 1161/4885LMNA 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.